Walvax Biotechnology Dirección

Dirección controles de criterios 2/4

We currently do not have sufficient information about the CEO.

Información clave

Runsheng Jiang

Chief Executive Officer (CEO)

CN¥3.7m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	8.4yrs
Participación del CEO	0.06%
Permanencia media de la dirección	7.2yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Sep 24

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Jun 19

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

May 23

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01

CEO

Runsheng Jiang (67 yo)

8.4yrs

Permanencia

CN¥3,724,200

Compensación

Mr. Runsheng Jiang serves as Director of Walvax Biotechnology Co., Ltd. since June 22, 2016 and serves as its President and served its Non-Independent Director.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Runsheng Jiang	Director & President	no data	CN¥3.72m	0.058% CN¥ 13.5m
Hua Zhou	Chief Financial Officer	10.4yrs	CN¥3.41m	0.048% CN¥ 11.0m
Yun Yan Wu	Director of Operations	7.1yrs	CN¥1.85m	0.042% CN¥ 9.8m
Jin Long Zhao	Chief Investment Officer	7.1yrs	CN¥1.87m	sin datos
Lin Yuan	Technical Director	7.3yrs	CN¥2.61m	sin datos
Wei Yao	Marketing Director	8.3yrs	CN¥2.53m	sin datos
Qing Gongsun	Director of Human Resources	7.3yrs	CN¥1.77m	0.050% CN¥ 11.7m
Jiankang Zhang	VP & Director	no data	CN¥2.38m	sin datos
Shao Zhong Dong	VP & Director	no data	CN¥2.53m	sin datos
Yu Ran Liu	Board Secretary	2.1yrs	CN¥1.46m	sin datos
Qingtang Duan	Engineering Director	1.3yrs	CN¥1.38m	sin datos
Changxiong Wu	Accounting Supervisor	no data	sin datos	sin datos

7.2yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: 300142's management team is seasoned and experienced (7.2 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Runsheng Jiang	Director & President	8.4yrs	CN¥3.72m	0.058% CN¥ 13.5m
Jiankang Zhang	VP & Director	4.5yrs	CN¥2.38m	sin datos
Shao Zhong Dong	VP & Director	2.8yrs	CN¥2.53m	sin datos
Yunchun Li	Chairman	15.4yrs	CN¥4.33m	1.7% CN¥ 393.9m
Zhen Huang	Vice Chairman	7.5yrs	CN¥5.56m	1.11% CN¥ 256.8m
Jianmei Zhao	Independent Director	4.3yrs	CN¥114.60k	sin datos
Shiqing Ding	Chairwoman of the Supervisory Board	4.3yrs	sin datos	sin datos
Yongwu Fan	Non-Independent Director	4.3yrs	CN¥83.70k	sin datos
Ting Yan	Director	3yrs	CN¥333.40k	0.0044% CN¥ 1.0m
Jinyu Zhu	Independent Director	2.1yrs	CN¥114.60k	sin datos
Ganghong Sun	Independent Director	2.1yrs	CN¥114.60k	sin datos
Lingbing Zeng	Independent Director	2.1yrs	CN¥114.60k	sin datos

4.3yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: 300142's board of directors are considered experienced (4.3 years average tenure).

Walvax Biotechnology Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Recent updates

Consensus revenue estimates fall by 11%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Walvax Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Price target decreased by 28% to CN¥13.00

Consensus revenue estimates fall by 16%

Price target decreased by 11% to CN¥17.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

First quarter 2024 earnings: EPS and revenues miss analyst expectations

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Consensus revenue estimates decrease by 11%

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 11% to CN¥21.00

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings: EPS misses analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Consensus revenue estimates fall by 12%

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target decreased by 9.8% to CN¥23.00

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Price target decreased by 25% to CN¥25.50

Consensus revenue estimates fall by 21%

Price target decreased by 8.1% to CN¥34.00

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023

Price target increased by 19% to CN¥37.00

Price target decreased by 9.1% to CN¥30.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 16%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥32.00

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.18 in 2Q 2021)

Walvax Biotechnology Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥36.00

Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2021

Consensus forecasts updated

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Third quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.24 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.052 in 2Q 2020)

Walvax Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 19, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.012 loss in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.65 (vs CN¥0.092 in FY 2019)

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥48.62

New 90-day low: CN¥36.53

New 90-day low: CN¥48.42

New 90-day low: CN¥48.82

Third quarter earnings released

Walvax Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

Earnings released

New 90-day high - CN¥71.98

Walvax Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 15, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta